168 related articles for article (PubMed ID: 32628337)
21. Large Cell Neuroendocrine Carcinoma of the Prostate: A Systematic Review and Pooled Analysis.
Tu X; Chang T; Nie L; Qiu S; Xu H; Huang Y; Bao Y; Liu Z; Yang L; Wei Q
Urol Int; 2019; 103(4):383-390. PubMed ID: 30965328
[TBL] [Abstract][Full Text] [Related]
22. Small cell carcinoma of the prostate.
Nadal R; Schweizer M; Kryvenko ON; Epstein JI; Eisenberger MA
Nat Rev Urol; 2014 Apr; 11(4):213-9. PubMed ID: 24535589
[TBL] [Abstract][Full Text] [Related]
23. Sarcomatoid carcinoma of the prostate: a study of 42 cases.
Hansel DE; Epstein JI
Am J Surg Pathol; 2006 Oct; 30(10):1316-21. PubMed ID: 17001164
[TBL] [Abstract][Full Text] [Related]
24. Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment.
Ichaoui H; Nasr SB; Gargouri F; Zribi A; Hermi A; Fendri S; Balti M; Ayari J; Khiari R; Msakni I; Mansouri N; Ghozzi S; Haddaoui A
Pan Afr Med J; 2019; 34():125. PubMed ID: 33708294
[TBL] [Abstract][Full Text] [Related]
25. Utility of NKX3.1 Immunostaining in the Detection of Metastatic Prostatic Carcinoma on Fine-Needle Aspiration Smears.
Gan Q; Joseph CT; Guo M; Zhang M; Sun X; Gong Y
Am J Clin Pathol; 2019 Sep; 152(4):495-501. PubMed ID: 31175351
[TBL] [Abstract][Full Text] [Related]
26. Expression of high molecular weight cytokeratin-A novel feature of aggressive and innate hormone-refractory prostatic adenocarcinoma.
Lu JG; Lo ET; Williams C; Ma B; Sherrod AE; Xiao GQ
Prostate; 2023 Apr; 83(5):462-469. PubMed ID: 36576021
[TBL] [Abstract][Full Text] [Related]
27. Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate.
Brammer JE; Lulla P; Lynch GR
Int J Clin Oncol; 2011 Dec; 16(6):722-5. PubMed ID: 21347630
[TBL] [Abstract][Full Text] [Related]
28. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.
Tran TA; Jennings TA; Ross JS; Nazeer T
Am J Surg Pathol; 1998 Mar; 22(3):347-54. PubMed ID: 9500777
[TBL] [Abstract][Full Text] [Related]
29. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
Osunkoya AO; Epstein JI
Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
[TBL] [Abstract][Full Text] [Related]
30. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
Evans AJ; Humphrey PA; Belani J; van der Kwast TH; Srigley JR
Am J Surg Pathol; 2006 Jun; 30(6):684-93. PubMed ID: 16723845
[TBL] [Abstract][Full Text] [Related]
31. Distinguishing atrophy and high-grade prostatic intraepithelial neoplasia from prostatic adenocarcinoma with and without previous adjuvant hormone therapy with the aid of cytokeratin 5/6.
Abrahams NA; Bostwick DG; Ormsby AH; Qian J; Brainard JA
Am J Clin Pathol; 2003 Sep; 120(3):368-76. PubMed ID: 14502799
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical changes in prostate cancer after androgen deprivation therapy.
Bostwick DG
Mol Urol; 2000; 4(3):101-6;discussion 107. PubMed ID: 11062363
[TBL] [Abstract][Full Text] [Related]
33. [Prostatic squamous cell cancer and its differential diagnostic contrast with squamous cell metaplasia].
Samsonov VA
Arkh Patol; 1984; 46(8):23-9. PubMed ID: 6208883
[TBL] [Abstract][Full Text] [Related]
34. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
35. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
36. Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes.
Topf MC; Tuluc M; Harshyne LA; Luginbuhl A
J Immunother Cancer; 2017 Jul; 5(1):60. PubMed ID: 28716144
[TBL] [Abstract][Full Text] [Related]
37. Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process.
Egan AJ; Lopez-Beltran A; Bostwick DG
Am J Surg Pathol; 1997 Aug; 21(8):931-5. PubMed ID: 9255256
[TBL] [Abstract][Full Text] [Related]
38. [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
Barbón JJ; González-Tuero J; Gay LL; Pérez-García FJ; Sampedro A
Arch Soc Esp Oftalmol; 2007 Nov; 82(11):715-7. PubMed ID: 17979041
[TBL] [Abstract][Full Text] [Related]
39. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
40. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.
Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A
Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
